BioNTech SE (ETR:22UA)
86.05
-1.05 (-1.21%)
Last updated: May 28, 2025
BioNTech SE Revenue
BioNTech SE had revenue of 182.80M EUR in the quarter ending March 31, 2025, a decrease of -2.56%. This brings the company's revenue in the last twelve months to 2.75B, up 0.61% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.75B
Revenue Growth
+0.61%
P/S Ratio
7.56
Revenue / Employee
405.54K
Employees
6,772
Market Cap
20.76B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
BioNTech SE News
- 7 days ago - BioNTech to invest $1.3B in the U.K. to boost R&D efforts - Seeking Alpha
- 8 days ago - The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. - Investor's Business Daily
- 8 days ago - BioNTech plans up to $1.33 billion investment in the United Kingdom - Reuters
- 10 days ago - Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny - Benzinga
- 13 days ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Wallstreet:Online
- 13 days ago - BioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimab - Seeking Alpha
- 22 days ago - Why BioNTech Stock Got Trounced on Tuesday - The Motley Fool
- 22 days ago - SA analyst downgrades: COP, ON, BNTX, SKX, ALIZY, SFM - Seeking Alpha